Mantle cell lymphoma diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Akram}} | {{CMG}}; {{AE}} {{Akram}} | ||
== Overview == | == Overview == | ||
Tissue [[biopsy]] (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma. | |||
== Diagnostic Study of Choice == | == Diagnostic Study of Choice == | ||
=== Study of choice === | === Study of choice === | ||
* '''Tissue biopsy''' (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma. | * '''Tissue biopsy''' (nodal or extranodal) is the gold standard [[test]] for the [[diagnosis]] of [[mantle cell lymphoma]]. | ||
==== Histology ==== | ==== Histology ==== | ||
* The microscopic histological findings can be found [[Mantle cell lymphoma pathophysiology #Microscopic Pathology|'''here''']]. | * The [[microscopic]] [[Histological|histological findings]] can be found [[Mantle cell lymphoma pathophysiology #Microscopic Pathology|'''here''']]. | ||
==== Immunohistochemistry ==== | ==== Immunohistochemistry ==== | ||
* CD19, CD20, CD22, CD43, CD79a, CD5, and FMC7 typically are positive, whereas CD23, CD10, CD200, and BCL6 are usually negative.<ref>{{Cite journal | * [[CD19]], [[CD20]], [[CD22]], [[CD43]], [[CD79a]], [[CD5]], and [[FMC7]] typically are positive, whereas [[CD23]], [[CD10]], [[CD200]], and [[BCL6]] are usually negative.<ref>{{Cite journal | ||
| author = [[Francesco Bertoni]], [[Emanuele Zucca]] & [[Finbarr E. Cotter]] | | author = [[Francesco Bertoni]], [[Emanuele Zucca]] & [[Finbarr E. Cotter]] | ||
| title = Molecular basis of mantle cell lymphoma | | title = Molecular basis of mantle cell lymphoma | ||
| Line 35: | Line 36: | ||
| pmid = 26755518 | | pmid = 26755518 | ||
}}</ref> | }}</ref> | ||
* Cyclin D1 is positive in majority of the cases. | * [[Cyclin D1]] is positive in majority of the cases. | ||
* SOX11 expression is useful if cyclin D1 is negative. | * [[SOX11]] expression is useful if [[cyclin D1]] is negative. | ||
*Ki-67 should also be included in the initial work-up. Ki-67 proliferation index of less than 30% is associated with a favorable prognosis.<ref>{{Cite journal | *[[Ki-67]] should also be included in the initial work-up. [[Ki-67]] proliferation index of less than 30% is associated with a favorable [[prognosis]].<ref>{{Cite journal | ||
| author = [[Olaf Determann]], [[Eva Hoster]], [[German Ott]], [[Heinz Wolfram Bernd]], [[Christoph Loddenkemper]], [[Martin Leo Hansmann]], [[Thomas E. F. Barth]], [[Michael Unterhalt]], [[Wolfgang Hiddemann]], [[Martin Dreyling]] & [[Wolfram Klapper]] | | author = [[Olaf Determann]], [[Eva Hoster]], [[German Ott]], [[Heinz Wolfram Bernd]], [[Christoph Loddenkemper]], [[Martin Leo Hansmann]], [[Thomas E. F. Barth]], [[Michael Unterhalt]], [[Wolfgang Hiddemann]], [[Martin Dreyling]] & [[Wolfram Klapper]] | ||
| title = Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group | | title = Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group | ||
| Line 62: | Line 63: | ||
==== Fluorescence in situ hybridization (FISH) ==== | ==== Fluorescence in situ hybridization (FISH) ==== | ||
* FISH can be used to detect the translocation t(11;14), which is found in most of MCL patients.<ref>{{Cite journal | * [[FISH]] can be used to detect the [[Chromosomal translocation|translocation]] t(11;14), which is found in most of [[MCL]] patients.<ref>{{Cite journal | ||
| author = [[Tsieh Sun]], [[Mary Lowery Nordberg]], [[James D. Cotelingam]], [[Diana M. Veillon]] & [[John Ryder]] | | author = [[Tsieh Sun]], [[Mary Lowery Nordberg]], [[James D. Cotelingam]], [[Diana M. Veillon]] & [[John Ryder]] | ||
| title = Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma | | title = Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma | ||
| Line 76: | Line 77: | ||
==== Karyotyping: ==== | ==== Karyotyping: ==== | ||
* Karyotyping can also be used to detect the translocation t(11;14), which is found in most of MCL patients.<ref>{{Cite journal | * [[Karyotyping]] can also be used to detect the [[translocation]] t(11;14), which is found in most of [[MCL]] patients.<ref>{{Cite journal | ||
| author = [[Jordi Camps]], [[Itziar Salaverria]], [[Maria J. Garcia]], [[Esther Prat]], [[Silvia Bea]], [[Jessica C. Pole]], [[Lluis Hernandez]], [[Javier Del Rey]], [[Juan Cruz Cigudosa]], [[Marta Bernues]], [[Carlos Caldas]], [[Dolors Colomer]], [[Rosa Miro]] & [[Elias Campo]] | | author = [[Jordi Camps]], [[Itziar Salaverria]], [[Maria J. Garcia]], [[Esther Prat]], [[Silvia Bea]], [[Jessica C. Pole]], [[Lluis Hernandez]], [[Javier Del Rey]], [[Juan Cruz Cigudosa]], [[Marta Bernues]], [[Carlos Caldas]], [[Dolors Colomer]], [[Rosa Miro]] & [[Elias Campo]] | ||
| title = Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines | | title = Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines | ||
Revision as of 19:59, 18 December 2018
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma diagnostic study of choice |
|
Risk calculators and risk factors for Mantle cell lymphoma diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]
Overview
Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.
Diagnostic Study of Choice
Study of choice
- Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.
Histology
- The microscopic histological findings can be found here.
Immunohistochemistry
- CD19, CD20, CD22, CD43, CD79a, CD5, and FMC7 typically are positive, whereas CD23, CD10, CD200, and BCL6 are usually negative.[1][2]
- Cyclin D1 is positive in majority of the cases.
- SOX11 expression is useful if cyclin D1 is negative.
- Ki-67 should also be included in the initial work-up. Ki-67 proliferation index of less than 30% is associated with a favorable prognosis.[3][4]
Fluorescence in situ hybridization (FISH)
- FISH can be used to detect the translocation t(11;14), which is found in most of MCL patients.[5]
Karyotyping:
- Karyotyping can also be used to detect the translocation t(11;14), which is found in most of MCL patients.[6]
References
- ↑ Francesco Bertoni, Emanuele Zucca & Finbarr E. Cotter (2004). "Molecular basis of mantle cell lymphoma". British journal of haematology. 124 (2): 130–140. PMID 14687022. Unknown parameter
|month=ignored (help) - ↑ Chan Yoon Cheah, John F. Seymour & Michael L. Wang (2016). "Mantle Cell Lymphoma". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34 (11): 1256–1269. doi:10.1200/JCO.2015.63.5904. PMID 26755518. Unknown parameter
|month=ignored (help) - ↑ Olaf Determann, Eva Hoster, German Ott, Heinz Wolfram Bernd, Christoph Loddenkemper, Martin Leo Hansmann, Thomas E. F. Barth, Michael Unterhalt, Wolfgang Hiddemann, Martin Dreyling & Wolfram Klapper (2008). "Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group". Blood. 111 (4): 2385–2387. doi:10.1182/blood-2007-10-117010. PMID 18077791. Unknown parameter
|month=ignored (help) - ↑ R. Schaffel, C. V. Hedvat, J. Teruya-Feldstein, D. Persky, J. Maragulia, D. Lin, C. S. Portlock, C. H. Moskowitz & A. D. Zelenetz (2010). "Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma". Annals of oncology : official journal of the European Society for Medical Oncology. 21 (1): 133–139. doi:10.1093/annonc/mdp495. PMID 20019090. Unknown parameter
|month=ignored (help) - ↑ Tsieh Sun, Mary Lowery Nordberg, James D. Cotelingam, Diana M. Veillon & John Ryder (2003). "Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma". American journal of hematology. 74 (1): 78–84. doi:10.1002/ajh.10356. PMID 12949897. Unknown parameter
|month=ignored (help) - ↑ Jordi Camps, Itziar Salaverria, Maria J. Garcia, Esther Prat, Silvia Bea, Jessica C. Pole, Lluis Hernandez, Javier Del Rey, Juan Cruz Cigudosa, Marta Bernues, Carlos Caldas, Dolors Colomer, Rosa Miro & Elias Campo (2006). "Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines". Leukemia research. 30 (8): 923–934. doi:10.1016/j.leukres.2005.11.013. PMID 16448697. Unknown parameter
|month=ignored (help)